Journal Article Summary
The article investigates the healthcare costs associated with the metabolic profiles of patients before and after one year of treatment with phentermine-topiramate extended-release (ER). This topic is significant due to the rising rates of obesity worldwide, which is linked to various health issues and increased medical expenses. Understanding the economic impact of weight-loss treatments like phentermine-topiramate ER can help inform patients and healthcare providers about potential cost savings and health benefits associated with weight management.
The study utilized a medical records database to create two patient groups that reflected the metabolic profiles of participants from the CONQUER trial, both before and after treatment. It analyzed healthcare utilization and costs over four years for 2,295 patients in each group. The findings indicated that, while the overall costs did not show a statistically significant difference between the two groups, those who responded to treatment (losing at least 5% of their body weight) experienced lower costs, particularly in outpatient visits and prescription medications.
However, the study has limitations, including the absence of long-term data on actual patients treated with phentermine-topiramate ER and the exclusion of treatment costs and potential side effects. Patients should be aware that while the study suggests possible cost savings for those who respond well to treatment, the safety and efficacy of phentermine-topiramate ER beyond one year remain uncertain. It is advisable for readers to discuss these findings and any concerns about weight-loss treatments with their healthcare professionals to make informed decisions tailored to their individual health needs.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Li James, Reaven Nancy L., Funk Susan E., McGaughey Karen, Neovius Martin. 4-Year Cost Trajectories in Real-World Patients Matched to the Metabolic Profiles of Trial Subjects Before/After Treatment with Phentermine-Topiramate. Drugs – Real World Outcomes 2015. DOI: 10.1007/s40801-015-0021-x. PMID: 27747764. PMCID: PMC4883189.
Featured Pill Pals Product
Topiramate 100 mg Tablet --- Generic For Topamax --- Zydus Pharma
Topiramate 100 mg Tablet — Generic For Topamax — Zydus Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
